ReviewAntibiotics (Basel, Switzerland)2020
FimH and Anti-Adhesive Therapeutics: A Disarming Strategy Against Uropathogens.
Review in Antibiotics (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 92 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
92 citing papers in PubMed, 2 syntheses or guidelines pooled it, 143 citations in OpenAlex.
- Efficacy and safety of Chinese patent medicine for urinary tract infections: a systematic review and network meta-analysis.Frontiers in medicine · 2025Pooled it
- Novel β-lactam antibiotics versus other antibiotics for treatment of complicated urinary tract infections: a systematic review and meta-analysis.Frontiers in pharmacology · 2024Pooled it
- Parallel evolutionary trajectories rewire enteropathogenicGut microbes · 2026Article
- Distribution of mrk genes among uopathogenic Klebsiella pneumoniae.Journal of applied genetics · 2026Article
- First Randomized Controlled Trial Comparing D-Mannose to Fosfomycin in Acute Uncomplicated Lower Urinary Tract Infections.Antibiotics (Basel, Switzerland) · 2026Article
- RstAB activates type 1 fimbriae to promote uropathogeniciScience · 2026Article
- Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2026Review
- Biofilm-based continuous secretion of human lysozyme through cell-surface display of FimH onSynthetic and systems biotechnology · 2026Article
- Distribution of acquired carbapenemase genes among uropathogenic Escherichia coli.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- An mRNA-based FimH nanoparticle vaccine against uropathogenicFrontiers in immunology · 2026Article
- Anti-infective compounds forSustainable microbiology · 2026Review
- Organosulfur compounds as dual-action agents: a critical review of antimicrobial and immunomodulatory potentials, and translational barriers.Frontiers in pharmacology · 2026Review
- Current Insights into Antibiotic Resistance in UropathogenicAntibiotics (Basel, Switzerland) · 2025Review
- Genomic Constellation of Foodborne Proteus Mirabilis Isolates Harboring AMR, Virulence Genes and Comparative WGS Analysis.Current microbiology · 2025Article
- Protein-Protein Interactions as Promising Molecular Targets for Novel Antimicrobials Aimed at Gram-Negative Bacteria.International journal of molecular sciences · 2025Review
- Mannose Derivatives as Anti-Infective Agents.International journal of molecular sciences · 2025Review
- Unveiling the Genomic Landscape of Escherichia coli O1:K1:H7 ST59 in Non-complicated Urinary Infections from Colombia Through Whole-Genome Sequencing.Current microbiology · 2025Article
- Beyond FimH: Diversity and Relevance of Carbohydrate-Binding Fimbrial Proteins in Escherichia coli.Chembiochem : a European journal of chemical biology · 2025Review
- Metatranscriptomics-based metabolic modeling of patient-specific urinary microbiome during infection.NPJ biofilms and microbiomes · 2025Article
- The global resistance problem and the clinical antibacterial pipeline.Nature reviews. Microbiology · 2025Review
32 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 2 countries.
Funding
Abstract
Chaperone-usher fimbrial adhesins are powerful weapons against the uropathogens that allow the establishment of urinary tract infections (UTIs). As the antibiotic therapeutic strategy has become less effective in the treatment of uropathogen-related UTIs, the anti-adhesive molecules active against fimbrial adhesins, key determinants of urovirulence, are attractive alternatives. The best-characterized bacterial adhesin is FimH, produced by uropathogenic
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.